Free Trial
→ The SpaceX supplier that shipped 5 billion chips to Starlink (From Weiss Ratings) (Ad)tc pixel Free NAVB Stock Alerts

Navidea Biopharmaceuticals (NAVB) Competitors

Navidea Biopharmaceuticals logo
Compare

NAVB vs. SCPS, VAXX, ELOX, ORGS, and TRVN

Should you buy Navidea Biopharmaceuticals stock or one of its competitors? MarketBeat compares Navidea Biopharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Navidea Biopharmaceuticals include Scopus BioPharma (SCPS), Vaxxinity (VAXX), Eloxx Pharmaceuticals (ELOX), Orgenesis (ORGS), and Trevena (TRVN). These companies are all part of the "pharmaceutical products" industry.

How does Navidea Biopharmaceuticals compare to Scopus BioPharma?

Scopus BioPharma (NASDAQ:SCPS) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Company Net Margins Return on Equity Return on Assets
Scopus BioPharmaN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Scopus BioPharma has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Scopus BioPharma has higher earnings, but lower revenue than Navidea Biopharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Scopus BioPharmaN/AN/A-$11.61MN/AN/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

In the previous week, Scopus BioPharma's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Scopus BioPharma Neutral
Navidea Biopharmaceuticals Neutral

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 5.1% of Scopus BioPharma shares are held by insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Navidea Biopharmaceuticals beats Scopus BioPharma on 4 of the 5 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Vaxxinity?

Navidea Biopharmaceuticals (NYSE:NAVB) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, indicating that its stock price is 7,537% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Vaxxinity N/A N/A N/A

Navidea Biopharmaceuticals has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 64.1% of Vaxxinity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Vaxxinity had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Vaxxinity and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Vaxxinity Neutral

Summary

Navidea Biopharmaceuticals and Vaxxinity tied by winning 4 of the 8 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Company Net Margins Return on Equity Return on Assets
Eloxx PharmaceuticalsN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Navidea Biopharmaceuticals has higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eloxx PharmaceuticalsN/AN/A-$36.06M-$1.39N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

In the previous week, Eloxx Pharmaceuticals had 2 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 2 mentions for Eloxx Pharmaceuticals and 0 mentions for Navidea Biopharmaceuticals. Eloxx Pharmaceuticals' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Eloxx Pharmaceuticals Neutral
Navidea Biopharmaceuticals Neutral

Eloxx Pharmaceuticals has a beta of -1907.33, meaning that its stock price is 190,833% less volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, meaning that its stock price is 76% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Eloxx Pharmaceuticals on 6 of the 8 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Orgenesis?

Navidea Biopharmaceuticals (NYSE:NAVB) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 1.9% of Orgenesis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Orgenesis. Orgenesis is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Orgenesis$662K4.61-$55.36M-$11.51N/A

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Orgenesis Neutral

Navidea Biopharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Orgenesis -3,827.81%N/A -130.18%

Navidea Biopharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.06, meaning that its share price is 206% more volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Orgenesis on 6 of the 9 factors compared between the two stocks.

How does Navidea Biopharmaceuticals compare to Trevena?

Navidea Biopharmaceuticals (NYSE:NAVB) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.

0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 13.6% of Trevena shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Comparatively, 2.7% of Trevena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Navidea Biopharmaceuticals has higher earnings, but lower revenue than Trevena. Trevena is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
Trevena$443K0.02-$40.29M-$47.04N/A

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Trevena has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Trevena N/A N/A -119.55%

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Trevena'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Trevena Neutral

Summary

Navidea Biopharmaceuticals beats Trevena on 5 of the 8 factors compared between the two stocks.

Get Navidea Biopharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NAVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NAVB vs. The Competition

Export
MetricNavidea BiopharmaceuticalsDiagnostic substances IndustryMedical SectorNYSE Exchange
Market Cap$10K$321K$6.46B$23.20B
Dividend YieldN/AN/A2.76%4.10%
P/E Ratio0.00N/A20.9930.65
Price / SalesN/A0.08560.3024.50
Price / CashN/AN/A43.4925.12
Price / BookN/AN/A10.414.74
Net Income-$15.18M-$6.86M$3.57B$1.07B

Navidea Biopharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
SCPS
Scopus BioPharma
N/A$0.00
flat		N/AN/A$25KN/AN/A9
VAXX
Vaxxinity
N/A$0.00
flat		N/A+0.0%$13KN/AN/A90
ELOX
Eloxx Pharmaceuticals
N/A$0.00
flat		N/AN/A$11KN/AN/A30
ORGS
Orgenesis
N/A$0.00
-95.3%		N/A-68.9%$11K$662KN/A150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:NAVB) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Trump Admin to Pump $1 Billion into this “Off-the-Radar” AI Stock
The U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...
InvestorPlace | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel